Check for updates

OPEN ACCESS

EDITED BY Roxana Adriana Stoica, Carol Davila University of Medicine and Pharmacy, Romania

REVIEWED BY Shen Yun, Heping Hospital Affiliated to Changzhi Medical College, China Andreea Nelson Twakor, County Clinical Emergency Hospital of Constanta, Romania

*CORRESPONDENCE Yufeng Gao ⊠ aygyf@ahmu.edu.cn

RECEIVED 28 April 2024 ACCEPTED 16 December 2024 PUBLISHED 07 January 2025

CITATION

Cui X, Huang Y, Kang L, Han L, Sun W, Han K and Gao Y (2025) A positive relationship between weight-adjusted waist index and non-alcoholic fatty liver disease: a study on US adolescents. *Front. Med.* 11:1424667. doi: 10.3389/fmed.2024.1424667

COPYRIGHT

© 2025 Cui, Huang, Kang, Han, Sun, Han and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

A positive relationship between weight-adjusted waist index and non-alcoholic fatty liver disease: a study on US adolescents

Xiaoling Cui^{1,2}, Yize Huang², Luyang Kang¹, Lianxiu Han¹, Weijie Sun¹, Kexing Han¹ and Yufeng Gao^{1*}

¹Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, China, ²Department of Infectious Diseases, Tongling People's Hospital, Tongling, Anhui, China

Background: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver condition in children, underscoring the urgent need for non-invasive markers for early detection in this population.

Methods: We utilized survey data from the National Health and Nutrition Examination Survey (NHANES) 2017–2020 regarding liver ultrasound transient elastography (LUTE) for the diagnosis of NAFLD (dependent variable), and used multiple logistic regression models to explore the association between weight-adjusted waist circumference index (WWI) and the prevalence of NAFLD in US adolescents. Smoothing curves and threshold effect analyses were used to assess the non-linear association between the independent variables and the dependent variable. Subgroup analysis was conducted to pinpoint particularly susceptible subgroups within our study cohort of 1,711 participants.

Results: Our findings indicated a positive correlation between WWI and NAFLD scores. Adjusting for all covariates revealed a significant association between increased WWI and the presence of NAFLD, with an odds ratio of 3.37 (95% CI: 2.74, 4.15). This association proved stronger than those observed with waist circumference, body mass index, and NAFLD. Stratifying WWI into quartiles showed a clear and strong positive correlation (*P* for trend < 0.0001). The results of smoothing curves and threshold effect analysis showed a non-linear relationship between WWI and NAFLD (LLR < 0.001). Notably, for WWI values below 10.65, a significant correlation was observed (OR = 5.25, 95% CI: 3.77,7.31). Additionally, our subgroup analysis revealed that WWI and NAFLD were associated more positively among male participants aged 16 years and older.

Conclusion: WWI is positively correlated with NAFLD in American adolescents and offers a straightforward and cost-effective method for identifying hepatic steatosis. The findings highlight the importance of focusing on individuals with a WWI below 10.65, where the risk of NAFLD increases. Priority should be given to the male adolescent population aged 16 and above.

KEYWORDS

non-alcoholic fatty liver disease, liver steatosis, adolescents, weight-adjusted waist index, BMI, waist circumference

1 Introduction

Non-alcoholic fatty liver disease (NAFLD) is characterized by fatty steatosis in more than 5% of liver cells, excluding alcohol consumption and other known causes (1, 2). It is now the most prevalent chronic liver disease in children and adolescents worldwide, with a prevalence rate of approximately 5%–11% (3, 4) and exceeding 50% in pediatric patients with other metabolic disorders (5). NAFLD can lead to progressive fibrosis and is a major contributor to the progression of end-stage liver disease, significantly increasing the demand for liver transplants (6, 7). Therefore, early detection of NAFLD in children and adolescents is crucial. Liver biopsy is considered the most accurate method for diagnosing pediatric NAFLD; however, due to its invasive nature and the potential for sampling errors, there is a significant need for non-invasive diagnostic techniques.

Several factors contribute to the development of NAFLD in young people, including weight gain, insulin resistance, central obesity, and other potential influences (8). In 2016, the World Health Organization (WHO) reported that over 340 million children and teenagers aged 5-19 years were classified as overweight or obese, highlighting the escalating global obesity crisis. The incidence of metabolism-related NAFLD in children and teenagers increased from 19.34 million in 1990 to 29.49 million in 2017, indicating a significant rise over the years (9). Recent data show that the prevalence of NAFLD linked to obesity among children and teenagers is 23.0% in Europe, 39.7% in South America, and 52.1% in Asia (10). Additionally, some studies have indicated that the growing obesity epidemic is strongly associated with an increased incidence and severity of NAFLD in children (11, 12). Consequently, the relationship between obesity indicators and NAFLD in children and adolescents is a major area of interest for researchers worldwide.

Risk factors that can influence NAFLD are often not singular, but previous studies have confirmed that it is usually associated with obesity (13). However, a significant proportion of patients with NAFLD do not appear to be obese in appearance, which makes screening for NAFLD challenging (14). The metrics that can be used to respond to a physical examination for obesity are diverse, and many of them have been shown to correlate with NAFLD (15, 16). The body mass index (BMI), a traditional measure of obesity, may fail to accurately identify a significant number of individuals with lean body mass and visceral obesity, raising questions about its accuracy (14, 17, 18). Waist circumference (WC), although an indicator of abdominal obesity, does not distinguish between visceral and subcutaneous adipose tissues and has been shown to correlate more strongly with subcutaneous fat (19). WC, for example, has been shown to be independently associated with increased cardiovascular risk, but its ability to predict visceral adipose tissue at the individual level remains limited (20). In response, Park et al. (21) introduced a novel obesity index in 2018 called the weight-adjusted waist index (WWI). This index, which is derived from both BMI and WC, offers a more precise measure of visceral obesity (21, 22). Research has confirmed that the accumulation of visceral fat is linked to a higher incidence of metabolic and endocrine disorders (23, 24). Oladimeji et al. (25) found that WWI was associated with blood pressure in a young population. Additionally, Park et al. (26) identified a positive linear correlation between WWI and type 2 diabetes mellitus. Elevated WWI has also been associated with an increased risk of cardiovascular death and overall mortality (27–29). However, to date, there have been no reports examining the relationship between WWI and NAFLD in adolescents.

2 Materials and methods

2.1 Data collection

National Health and Nutrition Examination Survey (NHANES) is administered by the CDC' National Center for Health Statistics (NCHS) and consists of questionnaires, physical examinations, and laboratory tests for selected participants. The physical examination module of the NHANES 2017–2020 survey data contained data from liver ultrasound transient elastography (LUTE). The NCHS Ethics Review Board approved the NHANES survey protocol, and all participants provided written informed consent. The study was exempt from ethical review because the NHANES database is available to the public.

2.2 Study participants

A total of 15,560 individuals were enrolled in the NHANES 2017-2020 cohort. In this cohort, participants aged 12 years and older were set to be able to take the FibroScan® test. Based on the ages set for children and adolescents in previous study (6-11 years old for children; 12-15 years old for adolescents, and 16-19 years old for late adolescents) (30), the 12-19 year olds were selected for this study (n = 2001). Participants lacking complete information on the LUTE test were excluded (n = 225), as were those missing necessary laboratory parameters for calculating the WWI, including weight (n = 14) and WC (n = 24). Following NHANES guidelines, individuals with the ratio of interquartile range to the median stiffness (IQR/M) of 30% or higher for liver stiffness measurements were also excluded (n = 22). Additionally, participants diagnosed with any other liver conditions were excluded (n = 5). Ultimately, 1,711 individuals were enrolled in the study. Further details about the participants are presented in Figure 1.

2.3 Determination of NAFLD

Liver ultrasound transient elastography provides objective measurements of hepatic fibrosis (scarring in the liver) and hepatic steatosis (fat in the liver). Liver fibrosis is measured with the FibroScan[®], which uses ultrasound and vibration-controlled transient elastography (VCTETM) to predict liver stiffness. The device also simultaneously measures the ultrasound attenuation associated with hepatic steatosis and records the Controlled Attenuation Parameter (CAPTM) as an indicator of liver fat content (31). The ultrasound-based FibroScan[®], which has been validated in multiple studies (32), is utilized for assessing liver steatosis. The collection of LUTE data in NHANES 2017–2020 required technicians to make at least



10 precise measurements, with the IQR/M of less than 30% as the primary data quality control criterion. The quality control criteria of IQR/M < 30% is to reduce variability and improve validity by taking measurements that result in few outliers. On this basis, and based on previous study, a median CAP of 248 dB/m or more is considered to be hepatic steatosis (4).

Importantly, during the period of our study (NHANES 2017–2020), the term NAFLD was used to describe the condition of fat accumulation in the liver without excessive alcohol consumption. Subsequent to our study period, in 2023, the terminology was updated to potentially include metabolic dysfunction-associated steatotic liver disease (MASLD), reflecting advancements in understanding the metabolic underpinnings of liver disease. However, as our analysis is based on NHANES data collected between 2017 and 2020, we have adhered to the NAFLD terminology prevalent during that time frame.

2.4 Calculation of WWI and BMI

Body mass index and WWI measurements were taken by certified medical professionals at the Mobile Exam Center (MEC). BMI is established by dividing the square of the height in meters by the weight in kilograms. In contrast, WWI is determined by dividing the square root of body weight (kg) by the WC (cm) (33). WC measurements were directly obtained from the recorded data. A review of NHANES body measurement data from 2017 to 2020 confirmed consistency across the study period.

2.5 Covariates

In previous studies, we adjusted the model to include additional variables (34, 35). Demographic variables include participant age, household income-to-poverty ratio (PIR) and race (classified as black, white, or other). Physical examination data encompasses height (cm), weight (kg), and WC (cm). Laboratory data comprises alanine aminotransferase (ALT) (U/L), gamma-glutamyl transaminase (GGT) (IU/L), uric acid (UA) (mg/dL), triglycerides (TG) (mg/dL), high-sensitivity C-reactive protein (HSCRP) (mg/L), white blood cell count (WBC) (1,000 cells/µl), platelet count (PLT) (1,000 cells/µl), ferritin (ng/ml), and glycohemoglobin (HbA1c) (%). To determine the presence of diabetes, prediabetes, and hypertension, participants were asked the following question: "Did your doctor tell you that you have diabetes, prediabetes, or high blood pressure?" In addition, we screened the selected covariates before constructing the final model. First, based on variance inflation factor (VIF), stepwise screening removed covariates with excessively high variances among them (VIF > 5) (Supplementary Table 1). Subsequently, according to the principle that the statistical significance *p*-value of regression coefficients introduced by the covariates should be <0.1 (Supplementary Table 2), the final included covariates were determined (Supplementary Table 3).

2.6 Statistical analysis

We utilized R and EmpowerStats to analyze all data in this study, and a P-value less than 0.05 was deemed statistically significant. The NHANES fieldwork was suspended in March 2020 due to the COVID-19 pandemic, resulting in an incomplete data collection cycle for 2019-2020. This disruption suggests that the findings may not fully represent the national population. To address this and create a nationally representative sample, data from the 2019 to March 2020 cycle was merged with information from the 2017 to 2018 NHANES cycle. We adhered to NHANES guidelines by using the check sample weights provided for the LUTE data analysis. Consequently, for the 2017-March 2020 period, special investigation sample weights (variable name: WTMECPRP) were used. The means and standard errors were utilized to depict continuous variables, while frequencies and percentages were employed to symbolize categorical variables. For continuous variables with no more than 10% missing values, missing data were imputed using the mean; otherwise, these variables were transformed into dichotomous variables using cutoffs defined by the reference ranges in the NHANES laboratory procedure manual, with missing values classified as a separate group. The association between NAFLD and independent variables (WWI, BMI, and WC) was assessed using multiple logistic regression models. Three models were adjusted: model 1 (unadjusted), model 2 (adjusted for age, race, and sex), and model 3 (adjusted for all covariates listed in Table 1). In order to identify sensitive individuals and evaluate the correlation between independent and dependent variables, subgroup analysis was then performed. In exploring the relationship between WWI and NAFLD, in order to ensure the accuracy and reliability of the results. We also paid special attention to the existence of non-linear relationships and their characteristics. First, we used smooth curve fitting analysis to confirm the existence of a non-linear relationship between WWI and NAFLD. This is because smoothed curve fitting analysis is a method of approximating data points by fitting a smooth curve, which could reveal underlying trends and patterns in the data, especially if the relationship between data points is not simply linear. Second, in order to determine the optimal inflection point (i.e., threshold point) among the independent variables of the WWI, we used threshold effects analysis. Threshold effect analysis is a method used to identify critical points where the relationship between variables changes significantly. Through this method, we were able to find the turning points when WWI affected NAFLD, which is critical to understanding how and when WWI began to significantly affect NAFLD. A log-likelihood ratio (LLR) of less than 0.05 was used to determine the significance of the non-linear relationships observed in the threshold effects analysis.

3 Results

3.1 Baseline characteristics of participants

This study included a total of 1,711 individuals, with an analysis of their general characteristics presented in Table 1. Statistically significant differences were noted in age, race, and PIR (P < 0.05) between the groups. Participants in the NAFLD group exhibited higher rates of diabetes, prediabetes, and hypertension. Furthermore, the NAFLD group had higher levels of ALT, GGT, UA, TG, HSCRP, WBC, PLT, ferritin, and HbA1c (P < 0.01), and a notable statistical disparity was observed in BMI, WC, and WWI between the two groups (P < 0.001).

3.2 The correlation between WWI and NAFLD

A positive correlation was observed between NAFLD and the variables BMI, WC, and WWI across all three models (models 1–3). The association between WWI and NAFLD was stronger than that between BMI and NAFLD, as well as WC and NAFLD. The final adjusted model showed that each unit increase in WWI increased the risk of developing NAFLD by 3.37% (OR = 3.37, 95% CI: 2.74, 4.15). This relationship persisted when WWI was categorized into quartiles, with the correlation strength increasing as WWI increased (P < 0.0001). In the highest quartile of WWI (10.57–13.27), a significant association was observed (OR = 11.65, 95% CI: 7.28, 18.65). Similarly, in the fourth quartile groups for BMI and WC, positive correlations were found between WC and NAFLD (OR = 20.69, 95% CI: 12.75, 33.59) and BMI and NAFLD (OR = 21.86, 95% CI: 13.26, 36.05). These results are summarized in Table 2.

3.3 Analysis by subgroups of the correlation between WWI and NAFLD

To verify the robustness of the positive correlation between WWI and NAFLD in specific demographic groups and to identify particularly vulnerable cohorts, we conducted a subgroup analysis. In the fully adjusted model, the results demonstrated a positive correlation between WWI and NAFLD among male participants (OR = 4.61, 95% CI: 3.39, 6.26) and those aged 16 years and older (OR = 3.51, 95% CI: 2.56, 4.82). These findings are detailed in Table 3. When analyzing BMI as the dependent variable, a stronger positive correlation was observed between BMI and NAFLD in males (OR = 1.32, 95% CI: 1.26, 1.39) and in individuals aged 16 and above (OR = 1.29, 95% CI: 1.23, 1.35), as shown in Table 4. Similarly, the correlation between WC and NAFLD was consistent when WC was analyzed as the response variable, detailed in Table 5.

3.4 Analysis of the threshold effect and smooth curve fitting for WWI with NAFLD

We explored the possibility of a non-linear relationship between WWI and NAFLD using smooth curve fitting and threshold effect analysis. The analysis revealed that the relationship was not linear, as depicted in Figure 2. Using the threshold effect model, a non-linear link was identified between WWI and NAFLD, with an LLR less than 0.001. Notably, the positive association between WWI and NAFLD intensified while WWI was below 10.65, as indicated by the effect value (OR = 5.25, 95% CI: 3.77, 7.31), shown in Figure 2A. Conversely, when WC was the dependent variable, a slight increase in NAFLD risk was noted (OR = 1.11, 95% CI: 1.09, 1.13) when WC exceeded 73.3 (LLR = 0.046), as seen in Figure 2B. Additionally, a modest rise in the prevalence of NAFLD was observed (OR = 1.31, 95% CI: 1.26, 1.36) when BMI was below 31.4 and used as the dependent variable (LLR < 0.001), presented in Figure 2C. The outcomes of the smooth curve fitting and threshold effect analyses are also summarized in Table 6.

4 Discussion

Non-alcoholic fatty liver disease is a multisystemic disease that increases the risk of liver-related complications as well as morbidity and mortality associated with cardiovascular disease. In adults, obesity, particularly abdominal obesity, is a recognized risk factor for NAFLD. In our study population aged 12–19 years, 80.13% of adolescents were found to be overweight or obese (Table 1). This is consistent with the findings of Ruiz et al. (36), who noted that obesity disproportionately affects adolescents within this age group. BMI and WC are commonly used indicators to assess obesity, and numerous studies have shown that high BMI and WC are positively associated with the development of NAFLD (37–40). However, there are currently no reports on the association between WWI findings and NAFLD in adolescents.

Our study confirmed that WWI is more relevant than BMI and WC for assessing the occurrence of NAFLD in adolescents. Moreover, when WWI was categorized into quartiles, the positive correlation with NAFLD increased as WWI increased. NAFLD in adolescents is a metabolic stress-related liver injury strongly associated with obesity and insulin resistance (41). The pathogenesis of NAFLD involves the "multiple-hit doctrine," which includes hepatic triglyceride deposition, inflammatory cytokines,

TABLE 1 Characteristics of participants.

| Characteristic | Non-NAFLD group (<i>n</i> = 1,248) | NAFLD group (<i>n</i> = 463) | <i>P</i> -value |
|-------------------------------|-------------------------------------|-------------------------------|-----------------|
| Gender (%) | | | 0.074 |
| Male | 51.52 | 56.37 | |
| Female | 48.48 | 43.63 | |
| Age (years) | 15.30 ± 2.27 | 15.61 ± 2.17 | 0.011 |
| Race (%) | | | 0.007 |
| White | 54.33 | 61.99 | |
| Black | 26.68 | 19.87 | |
| Other race | 18.99 | 18.14 | |
| PIR (%) | | | 0.039 |
| <1.35 | 35.74 | 39.74 | |
| 1.35–3.45 | 30.37 | 32.18 | |
| > 3.45 | 22.76 | 16.41 | |
| Unclear | 11.14 | 11.66 | |
| Hypertension (%) | | | 0.008 |
| Yes | 12.66 | 17.71 | |
| No | 87.34 | 82.29 | |
| Diabetes and prediabetes (%) | | | < 0.001 |
| Yes | 2.00 | 7.56 | |
| No | 97.92 | 91.79 | |
| Unclear | 0.08 | 0.65 | |
| ALT (U/L) (%) | | | <0.001 |
| Male \geq 26, Female $>$ 22 | 5.93 | 27.65 | |
| Male < 26 , Female ≤ 22 | 80.69 | 60.26 | |
| Unclear | 13.38 | 12.10 | |
| GGT (U/L) (%) | | | < 0.001 |
| ≤33 | 84.62 | 79.05 | |
| >33 | 2.00 | 8.86 | |
| Unclear | 13.38 | 12.10 | |
| UA (mg/dl) (%) | | | <0.001 |
| ≤7.0 | 82.77 | 74.08 | |
| >7.0 | 3.85 | 13.82 | |
| Unclear | 13.38 | 12.10 | |
| TG (mg/dl) (%) | | | < 0.001 |
| ≤150 | 80.53 | 68.25 | |
| >150 | 6.09 | 19.65 | |
| Unclear | 13.38 | 12.10 | |
| HSCRP (mg/L) (%) | | | < 0.001 |
| <5 | 81.33 | 69.98 | |
| ≥5 | 5.29 | 17.71 | |
| Unclear | 13.38 | 12.31 | |
| WBC (1,000 cells/µl) | 6.69 ± 1.86 | 7.78 ± 2.15 | <0.001 |
| PLT (1,000 cells/µl) | 262.02 ± 54.89 | 280.78 ± 57.36 | <0.001 |
| Ferritin (ng/ml) | 54.46 ± 40.99 | 68.14 ± 60.88 | <0.001 |

(Continued)

TABLE 1 (Continued)

| Characteristic | Non-NAFLD group (<i>n</i> = 1,248) | NAFLD group (<i>n</i> = 463) | <i>P</i> -value |
|------------------------------------|-------------------------------------|-------------------------------|-----------------|
| HbA1c (%) | 5.26 ± 0.38 | 5.35 ± 0.65 | < 0.001 |
| BMI (kg/m ²) | 22.63 ± 4.68 | 30.68 ± 7.51 | < 0.001 |
| Under weight and normal weight (%) | 70.83 | 19.87 | < 0.001 |
| Overweight and obese | 29.17 | 80.13 | < 0.001 |
| WC (cm) | 77.66 ± 11.23 | 98.46 ± 17.34 | < 0.001 |
| WWI | 9.94 ± 0.70 | 10.69 ± 0.77 | < 0.001 |

Median and quartiles for continuous variables: P-value was calculated by weighted linear regression model. % for categorical variables: P-value as calculated by weighted Chi-square test.

TABLE 2 Association of BMI, WC, and WWI with NAFLD.

| Exposure | Model 1 OR (95% CI) | Model 2 OR (95% CI) | Model 3 OR (95% CI) | |
|--------------------------|----------------------|----------------------|----------------------|--|
| NAFLD | | | | |
| BMI (kg/m ²) | 1.25 (1.22, 1.28) | 1.28 (1.24, 1.31) | 1.25 (1.21, 1.29) | |
| Quartiles of BMI | | | | |
| Q1 (13.2–20.1) | Reference | Reference | Reference | |
| Q2 (20.2–23.1) | 1.66 (0.99, 2.76) | 1.79 (1.07, 3.01) | 1.73 (1.02, 2.94) | |
| Q3 (23.2–27.7) | 5.25 (3.34, 8.24) | 5.72 (3.60, 9.09) | 4.86 (3.02, 7.81) | |
| Q4 (27.8–59.4) | 29.32 (18.81, 45.71) | 36.87 (23.07, 58.90) | 21.86 (13.26, 36.05) | |
| <i>P</i> for trend | <0.0001 | <0.0001 | <0.0001 | |
| WC (cm) | 1.11 (1.09, 1.12) | 1.11 (1.10, 1.12) | 1.10 (1.09, 1.12) | |
| Quartiles of WC | | | | |
| Q1 (53.5–71.2) | Reference | Reference | Reference | |
| Q2 (71.3–79.4) | 1.31 (0.79, 2.18) | 1.31 (0.79, 2.20) | 1.21 (0.72, 2.04) | |
| Q3 (79.5–92.0) | 4.22 (2.73, 6.54) | 4.28 (2.73, 6.70) | 3.77 (2.37, 5.98) | |
| Q4 (92.1–157.9) | 30.85 (20.09, 47.39) | 32.13 (20.61, 50.09) | 20.69 (12.75, 33.59) | |
| <i>P</i> for trend | <0.0001 | <0.0001 | <0.0001 | |
| WWI | 3.78 (3.20, 4.47) | 4.94 (4.09, 5.96) | 3.37 (2.74, 4.15) | |
| Quartiles of WWI | | | | |
| Q1 (7.89–9.55) | Reference | Reference | Reference | |
| Q2 (9.56–10.07) | 1.69 (1.09, 2.65) | 2.19 (1.38, 3.47) | 1.94 (1.22, 3.11) | |
| Q3 (10.08–10.56) | 5.12 (3.43, 7.65) | 8.61 (5.55, 13.36) | 5.82 (3.70, 9.16) | |
| Q4 (10.57–13.27) | 14.07 (9.48, 20.87) | 25.00 (16.05, 38.92) | 11.65 (7.28, 18.65) | |
| P for trend | <0.0001 | <0.0001 | <0.0001 | |

Model 1: no covariates were adjusted; model 2: age, gender, and race were adjusted; model 3: all covariates were adjusted.

free fatty acids, intestinal microecology, and genetic inheritance (42). Obesity is the most common cause of childhood and adolescent liver disease. Research has substantiated the strong correlation between obesity, metabolic disorders, and inflammation (43–45). Excess body fat, particularly visceral fat, promotes elevated blood pressure, insulin resistance, and atherosclerosis through the action of adipocytokines produced by the adipose tissue (46). Furthermore, adipocytokines enhance insulin resistance and induce systemic inflammation and oxidative stress, which promote the formation of NAFLD (47). Therefore, it appears that the initiation of obesity plays a critical role in the etiology of NAFLD and potentially in the progression to NASH.

Body mass index and WC are two common indicators of obesity (48). However, changes in the height and weight

components of BMI may represent physiological rather than pathological states in children and adolescents. WC, while highly correlated with BMI, does not accurately capture the full extent of obesity. The standardized WWI has proven more accurate in assessing obesity and is more closely associated with morbidity and mortality from obesity-related diseases (28, 49). Hu et al. (37) reported a positive association between WWI and NAFLD in adults aged 20 years and older (37). Shen et al. (50) demonstrated an increase in the CAP of 7.6 dB/m for each unit increase in WWI among US adults. However, an association between WWI and NAFLD has not yet been reported in pediatric and adolescent populations. Our study showed that WWI was more accurate in predicting NAFLD in children and adolescents (OR = 3.37, 95% CI: 2.74, 4.15). Particularly, the correlation between WWI and NAFLD TABLE 3 Subgroup analysis of association between WWI and NAFLD.

| Characteristic | Model 1 OR (95% CI) | Model 2 OR (95% CI) | Model 3 OR (95% CI) | |
|---------------------------|---------------------|---------------------|---------------------|--|
| Stratified by gender | | | | |
| Male | 4.59 (3.63, 5.80) | 6.38 (4.84, 8.41) | 4.61 (3.39, 6.26) | |
| Female | 3.86 (2.97, 5.01) | 3.95 (3.00, 5.20) | 2.68 (1.96, 3.65) | |
| Stratified by age (years) | | | | |
| <16 | 3.66 (2.90, 4.62) | 3.83 (3.00, 4.88) | 2.86 (2.19, 3.75) | |
| ≥16 | 4.14 (3.24, 5.30) | 5.47 (4.14, 7.24) | 3.51 (2.56, 4.82) | |
| Stratified by race | | | | |
| White | 3.89 (3.10, 4.87) | 5.22 (4.03, 6.75) | 3.77 (2.83, 5.02) | |
| Black | 3.25 (2.39, 4.42) | 4.23 (2.94, 6.09) | 3.08 (1.99, 4.77) | |
| Other race | 4.44 (2.87, 6.85) | 6.23 (2.66, 9.79) | 3.98 (2.26, 7.02) | |

Model 1: no covariates were adjusted; Model 2: age, gender, race were adjusted. Model 3: all covariates were adjusted.

TABLE 4 Subgroup analysis of association between BMI and NAFLD.

| Characteristics | Model 1 OR (95% CI) | Model 2 OR (95% CI) | Model 3 OR (95% CI) | | |
|---------------------------|---------------------|---------------------|---------------------|--|--|
| Stratified by gender | | | | | |
| Male | 1.34 (1.28, 1.40) | 1.35 (1.29, 1.41) | 1.32 (1.26, 1.39) | | |
| Female | 1.21 (1.17, 1.24) | 1.23 (1.19, 1.27) | 1.21 (1.16, 1.26) | | |
| Stratified by age (years) | | | | | |
| <16 | 1.25 (1.20, 1.29) | 1.26 (1.22, 1.31) | 1.24 (1.19, 1.29) | | |
| ≥16 | 1.26 (1.22, 1.31) | 1.29 (1.24, 1.34) | 1.29 (1.23, 1.35) | | |
| Stratified by race | | | | | |
| White | 1.30 (1.25, 1.34) | 1.31 (1.26, 1.36) | 1.29 (1.24, 1.35) | | |
| Black | 1.18 (1.13, 1.22) | 1.20 (1.15, 1.25) | 1.19 (1.13, 1.25) | | |
| Other race | 1.37 (1.27, 1.48) | 1.39 (1.29, 1.51) | 1.36 (1.24, 1.49) | | |

TABLE 5 Subgroup analysis of association between WC and NAFLD.

| Characteristics | Model 1 OR (95% CI) | Model 2 OR (95% CI) | Model 3 OR (95% CI) | |
|---------------------------|---------------------|---------------------|---------------------|--|
| Stratified by gender | | | | |
| Male | 1.12 (1.10, 1.14) | 1.12 (1.11, 1.14) | 1.12 (1.10, 1.14) | |
| Female | 1.09 (1.08, 1.11) | 1.10 (1.08, 1.12) | 1.10 (1.07, 1.12) | |
| Stratified by age (years) | | | | |
| <16 | 1.10 (1.09, 1.12) | 1.10 (1.09, 1.12) | 1.10 (1.08, 1.12) | |
| ≥16 | 1.11 (1.10, 1.13) | 1.12 (1.10, 1.13) | 1.12 (1.09, 1.14) | |
| Stratified by race | | | | |
| White | 1.12 (1.10, 1.13) | 1.12 (1.10, 1.14) | 1.12 (1.10, 1.14) | |
| Black | 1.07 (1.06, 1.09) | 1.08 (1.06, 1.10) | 1.08 (1.05, 1.10) | |
| Other race | 1.14 (1.11, 1.18) | 1.15 (1.11, 1.19) | 1.16 (1.11, 1.21) | |

was more pronounced when WWI was below 10.65 (OR = 5.25, 95% CI: 3.77, 7.31).

From the subgroup analysis, we concluded that male adolescents aged 16 and older require particular attention in NAFLD screening. Multiple meta-analyses and epidemiological studies have found that the incidence of NAFLD is significantly higher in males than in females. A recent prospective cohort study showed a stronger positive correlation between abdominal adipose tissue and the cumulative incidence of NAFLD in men compared to women (51). Men have a lower risk of subcutaneous fat distribution in the buttocks and femurs and a higher risk of visceral obesity, which is mainly characterized in women by accumulation in the buttocks, limbs, and subcutaneous fat. Compared to abdominal adipose tissue, the lipolytic response of gluteal femoral fat to epinephrine and norepinephrine is lower, releasing fewer fatty acids, while estradiol reduces lipolysis, resulting in fewer fatty acids delivered to the liver. Body and visceral fat content increase with age. A cross-sectional study assessing NAFLD in 33,216



The association of BMI, WC, and WWI with NAFLD. Red band represents a smooth curve fit between the variables. The blue bands represent the 95% confidence intervals of the fitted results. The independent variables were BMI (kg/m²) (A), WC (cm) (B), and WWI (C). All the covariates in Table 1 were adjusted.

TABLE 6 Threshold effect analysis of the association of BMI, WC, and WWI with NAFLD.

| Exposure | BMI | WC | WWI | |
|---|-------------------|-------------------|-------------------|--|
| Linear model | | | | |
| OR (95% CI) | 1.25 (1.21, 1.29) | 1.10 (1.09, 1.12) | 3.37 (2.74, 4.15) | |
| Non-linear model | | | | |
| Inflection point (K) | 31.4 | 73.3 | 10.65 | |
| OR (95% CI) (<k)< td=""><td>1.31 (1.26, 1.36)</td><td>1.03 (0.96, 1.10)</td><td>5.25 (3.77, 7.31)</td></k)<> | 1.31 (1.26, 1.36) | 1.03 (0.96, 1.10) | 5.25 (3.77, 7.31) | |
| OR (95% CI) (>K) | 1.12 (1.05, 1.19) | 1.11 (1.09, 1.13) | 1.73 (1.15, 2.61) | |
| LLR | <0.001 | 0.046 | <0.001 | |

Spaniards aged 18-65 years showed that NAFLD prevalence was more pronounced in males and increased with age (52). Similar results were observed in a prospective cohort study of children and adolescents, where the prevalence of fatty liver was 2.38% in students under 8 years and 24.76% in students over 17 years, with a higher prevalence of severe fatty liver among high school students (53). Previous study demonstrated a correlation between low serum testosterone and NAFLD or even cirrhosis due to NAFLD and was associated with poor clinical outcomes (54), a feature that was more pronounced in male patients. In a cross-sectional study, WWI was shown to correlate with a decrease in total serum testosterone and was more pronounced in males in late adolescence (16-19 years old) (55). Therefore, we suggested that male adolescents aged 16 years and older may have attenuated the protective effect of testosterone against hepatic steatosis due to the reduction in total testosterone resulting from higher WWI.

To our knowledge, this is the first cross-sectional study to explore the association between WWI and NAFLD in pediatric and adolescent populations. According to the NASPGHAN clinical practice guidelines for the diagnosis and treatment of NAFLD in children (56), there are limitations with using ALT as the preferred first-line screening indicator due to its inadequate sensitivity and specificity (57, 58). Consequently, conventional ultrasound, which also lacks adequate sensitivity and specificity, is not recommended for NAFLD screening programs in children. Therefore, WWI has the potential to be used as a screening indicator for NAFLD in children and adolescents. However, there were some limitations to this study. First, the use of ultrasound fiber scanning for the diagnosis of NAFLD has some limitations. Although fiber scanning had been validated in several studies and was considered a reliable tool for assessing hepatic steatosis and fibrosis (35), it has its own limitations. For example, the CAP derived from fiber scans can estimate liver fat content but is not as accurate as liver biopsy, which remains the gold standard for diagnosing NAFLD. In addition, LUTE may be affected by factors such as liver inflammation, bile duct obstruction, and iron overload during operation, which may lead to misclassification in some cases (59). Meanwhile, inter- and intra-observer variability in CAP measurements, although generally low, cannot be completely ignored. All of these factors may lead to bias in our results, and thus further validation using more explicit diagnostic methods is needed in future studies. Second, the cross-sectional design of our study limited our ability to determine causality. Although our findings indicated a strong positive association between WWI and NAFLD, this design did not allow us to infer a causal relationship between the two. The currently observed association may be due to unmeasured confounders or reverse causality. For example, patients with NAFLD may have a change in body composition that leads to an increase in WWI, rather than the other way around. To address this limitation, longitudinal studies are necessary to track changes in WWI over time and its relationship to the onset and progression of NAFLD. Third, the generalizability of our findings may be limited by the specificity of the study population. Our study focused on adolescents aged 12-19 years in the United States,

and the findings may not be applicable to other age groups or populations of different ethnicities and races. Future studies involving more diverse population groups are necessary to confirm the broad applicability of our findings. Finally, the COVID-19 pandemic disrupted data collection in 2020 and may have affected the representativeness of our sample. In conclusion, while our study provided valuable insights into the relationship between WWI and NAFLD in adolescents, further research is needed to address these limitations and confirm our findings. Prospective studies in larger, more diverse populations, combined with more definitive diagnostic methods, will help solidify the role of WWI as a potential screening tool for NAFLD in pediatric and adolescent populations.

5 Conclusion

This study found a non-linear positive association between WWI and NAFLD in US adolescents. This non-linear positive association was more significant at WWI below 10.65. The positive association between WWI and NAFLD was stronger in male adolescents aged 16 years and older. Thus, WWI is useful as a simple and economical indicator to identify hepatic steatosis in adolescents.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Author contributions

XC: Writing – original draft, Writing – review & editing. YG: Writing – original draft, Writing – review & editing. YH: Supervision, Writing – review & editing. LK: Writing – review & editing. LH: Writing – review & editing. WS: Writing – review & editing. KH: Writing – review & editing.

References

1. Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. *Hum Pathol.* (2004) 35:1070–82. doi: 10.1016/j.humpath. 2004.04.017

2. Ralli EP, Paley K, Rubin SH. The liver lipids and their distribution in disease. An analysis of 60 human livers 1. *J Clin Invest.* (1941) 20:413–7. doi: 10.1172/JCI101236

3. Yu EL, Schwimmer JB. Epidemiology of pediatric nonalcoholic fatty liver disease. *Clin Liver Dis (Malden, Mass.).* (2021) 17:196–9. doi: 10.1002/cld.1027

4. Ciardullo S, Monti T, Perseghin G. Prevalence of liver steatosis and fibrosis detected by transient elastography in adolescents in the 2017–2018 national health and nutrition examination survey. *Clin Gastroenterol Hepatol.* (2021) 19:384–90. doi: 10.1016/j.cgh.2020.06.048

5. Anderson EL, Howe LD, Jones HE, Higgins JPT, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. *PLoS One.* (2015) 10:e140908. doi: 10.1371/journal.pone. 0140908

6. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was supported by the Natural Science Foundation of Anhui Province (2208085MH204).

Acknowledgments

We would like to thank all NHANES participants and staff.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2024. 1424667/full#supplementary-material

adults awaiting liver transplantation in the United States. *Gastroenterology*. (2015) 148:547–55. doi: 10.1053/j.gastro.2014.11.039

7. Fleischman MW, Budoff M, Zeb I, Li D, Foster T. NAFLD prevalence differs among hispanic subgroups: the multi-ethnic study of atherosclerosis. *World J Gastroenterol.* (2014) 20:4987–93. doi: 10.3748/wjg.v20.i17. 4987

8. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. *J Hepatol.* (2017) 67:862–73. doi: 10.1016/j.jhep.2017.06.003

9. Vespoli C, Mohamed Iqbal A, Nasser Kabbany M, Radhakrishnan K. Metabolic-associated fatty liver disease in childhood and adolescence. *Endocrinol Metab Clin North Am.* (2023) 52:417–30. doi: 10.1016/j.ecl.2023. 02.001

10. Obita G, Alkhatib A. Disparities in the prevalence of childhood obesity-related comorbidities: a systematic review. *Front Public Health.* (2022) 10:923744. doi: 10. 3389/fpubh.2022.923744

11. Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. *Metabolism*. (2019) 92:82–97. doi: 10. 1016/j.metabol.2018.11.014

12. Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, et al. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - evidence from three different disease models: NAFLD, HCV and HIV. *World J Gastroenterol.* (2016) 22:9674–93. doi: 10.3748/wjg.v22.i44. 9674

13. Omaña-Guzmán I, Rosas-Diaz M, Martínez-López YE, Perez-Navarro LM, Diaz-Badillo A, Alanis A, et al. Strategic interventions in clinical randomized trials for metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity in the pediatric population: a systematic review with meta-analysis and bibliometric analysis. *BMC Med.* (2024) 22:548. doi: 10.1186/s12916-024-03744-x

14. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol.* (2018) 15:11–20. doi: 10.1038/nrgastro.2017.109

15. Lin XY, Li JM, Huang LY, Lin LY, Hong MZ, Weng S, et al. A significant and persistent rise in the global burden of adolescent NAFLD and NASH estimated by BMI. *Front Public Health*. (2024) 12:1437432. doi: 10.3389/fpubh.2024.1437432

16. Xie W, Hong Y, Chen X, Wang S, Zhang F, Chi X. Waist-to-hip ratio and nonalcoholic fatty liver disease: a clinical observational and Mendelian randomization analysis. *Front Nutr.* (2024) 11:1426749. doi: 10.3389/fnut.2024.1426749

17. Heymsfield SB, Scherzer R, Pietrobelli A, Lewis CE, Grunfeld C. Body mass index as a phenotypic expression of adiposity: quantitative contribution of muscularity in a population-based sample. *Int J Obes (Lond)*. (2009) 33:1363–73. doi: 10.1038/ijo.2009. 184

18. Javed A, Jumean M, Murad MH, Okorodudu D, Kumar S, Somers VK, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity in children and adolescents: a systematic review and meta-analysis. *Pediatr Obes.* (2015) 10:234–44. doi: 10.1111/ijpo.242

19. Wang S, Zhang J, Zhang W, Wang H, Hou J, Zhang R, et al. [Predictive value of body mass index combined with waist circumference for new-onset nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus]. *Nan Fang Yi Ke Da Xue Xue Bao.* (2019) 39:1293–7. doi: 10.12122/j.issn.1673-4254.2019.11.05

20. Tao J, Zhang Y, Tan C, Tan W. Associations between weight-adjusted waist index and fractures: a population-based study. J Orthop Surg Res. (2023) 18:290. doi: 10.1186/s13018-023-03776-8

21. Park Y, Kim NH, Kwon TY, Kim SG. A novel adiposity index as an integrated predictor of cardiometabolic disease morbidity and mortality. *Sci Rep.* (2018) 8:16753. doi: 10.1038/s41598-018-35073-4

 Tutunchi H, Naeini F, Ebrahimi-Mameghani M, Najafipour F, Mobasseri M, Ostadrahimi A. Metabolically healthy and unhealthy obesity and the progression of liver fibrosis: a cross-sectional study. *Clin Res Hepatol Gastroenterol.* (2021) 45:101754. doi: 10.1016/j.clinre.2021.101754

23. Nomura K, Eto M, Kojima T, Ogawa S, Iijima K, Nakamura T, et al. Visceral fat accumulation and metabolic risk factor clustering in older adults. *J Am Geriatr Soc.* (2010) 58:1658–63. doi: 10.1111/j.1532-5415.2010.03018.x

24. Tatsumi Y, Nakao YM, Masuda I, Higashiyama A, Takegami M, Nishimura K, et al. Risk for metabolic diseases in normal weight individuals with visceral fat accumulation: a cross-sectional study in Japan. *BMJ Open.* (2017) 7:e13831. doi: 10. 1136/bmjopen-2016-013831

25. Oladimeji A, Oiwoh SO, Kehinde K, Adedayo W, Oluwafemi AO, Oluwaseyi FO, et al. Relationship between selected traditional & novel anthropometric parameters and blood pressure among young people. *West Afr J Med.* (2023) 40:S12–3.

26. Park MJ, Hwang SY, Kim NH, Kim SG, Choi KM, Baik SH, et al. A novel anthropometric parameter, weight-adjusted waist index represents sarcopenic obesity in newly diagnosed type 2 diabetes mellitus. *J Obes Metab Syndr.* (2023) 32:130–40. doi: 10.7570/jomes23005

27. Ding C, Shi Y, Li J, Li M, Hu L, Rao J, et al. Association of weight-adjusted-waist index with all-cause and cardiovascular mortality in China: a prospective cohort study. *Nutr Metab Cardiovasc Dis.* (2022) 32:1210–7. doi: 10.1016/j.numecd.2022.01.033

28. Fang H, Xie F, Li K, Li M, Wu Y. Association between weight-adjusted-waist index and risk of cardiovascular diseases in United States adults: a cross-sectional study. *BMC Cardiovasc Disord*. (2023) 23:435. doi: 10.1186/s12872-023-03452-z

29. Cai S, Zhou L, Zhang Y, Cheng B, Zhang A, Sun J, et al. Association of the weight-adjusted-waist index with risk of all-cause mortality: a 10-year follow-up study. *Front Nutr.* (2022) 9:894686. doi: 10.3389/fnut.2022.89 4686

30. Tao C, Fan Y, Niu R, Li Z, Qian H, Yu H, et al. Urinary polycyclic aromatic hydrocarbons and sex hormones in children and adolescents: evidence from NHANES. *Ecotoxicol Environ Saf.* (2021) 216:112215. doi: 10.1016/j.ecoenv.2021.11 2215

31. Sasso M, Audière S, Kemgang A, Gaouar F, Corpechot C, Chazouillères O, et al. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the fibroscan: a pilot study assessing diagnostic accuracy. *Ultrasound Med Biol.* (2016) 42:92–103. doi: 10.1016/j.ultrasmedbio.2015.08.008

32. Zhao E, Wen X, Qiu W, Zhang C. Association between body roundness index and risk of ultrasound-defined non-alcoholic fatty liver disease. *Heliyon.* (2024) 10:e23429. doi: 10.1016/j.heliyon.2023.e23429

33. Qin Z, Chang K, Yang Q, Yu Q, Liao R, Su B. The association between weight-adjusted-waist index and increased urinary albumin excretion in adults: a population-based study. *Front Nutr.* (2022) 9:941926. doi: 10.3389/fnut.2022.941926

34. Clinical Practice EASL. Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. *J Hepatol*. (2021) 75:659–89. doi: 10.1016/j.jhep.2021.05.025

35. Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. *Gastroenterology*. (2019) 156:1717–30. doi: 10.1053/j.gastro.2019.01.042

36. Ruiz LD, Zuelch ML, Dimitratos SM, Scherr RE. Adolescent obesity: diet quality, psychosocial health, and cardiometabolic risk factors. *Nutrients.* (2019) 12:43. doi: 10.3390/nu12010043

37. Hu Q, Han K, Shen J, Sun W, Gao L, Gao Y. Association of weight-adjusted-waist index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study based on NHANES. *Eur J Med Res.* (2023) 28:263. doi: 10.1186/s40001-023-01205-4

38. Moran-Lev H, Cohen S, Webb M, Yerushalmy-Feler A, Amir A, Gal DL, et al. Higher BMI predicts liver fibrosis among obese children and adolescents with NAFLD - an interventional pilot study. *BMC Pediatr.* (2021) 21:385. doi: 10.1186/s12887-021-02839-1

39. Xing Y, Zhang P, Li X, Jin S, Xu M, Jia J, et al. New predictive models and indices for screening MAFLD in school-aged overweight/obese children. *Eur J Pediatr.* (2023) 182:5025–36. doi: 10.1007/s00431-023-05175-x

40. Chen BR, Pan CQ. Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease. *Clin Res Hepatol Gastroenterol.* (2022) 46:101755. doi: 10.1016/j.clinre.2021.101755

41. Kang E, Hong YH, Kim J, Chung S, Kim KK, Haam JH, et al. Obesity in children and adolescents: 2022 update of clinical practice guidelines for obesity by the Korean society for the study of obesity. *J Obes Metab Syndr.* (2024) 33:11–9. doi: 10.7570/jomes23060

42. Muzuroviæ E, Polyzos SA, Mikhailidis DP, Borozan S, Novosel D, Cmiljaniæ O, et al. Non-alcoholic fatty liver disease in children. *Curr Vasc Pharmacol.* (2023) 21:4–25. doi: 10.2174/1570161121666221118155136

43. Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. *Annu Rev Pathol.* (2018) 13:321–50. doi: 10.1146/ annurev-pathol-020117-043617

44. Ota T. Molecular mechanisms of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH). *Adv Exp Med Biol.* (2021) 1261:223–9. doi: 10.1007/978-981-15-7360-6_20

45. Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. *Nat Rev Immunol.* (2022) 22:429–43. doi: 10.1038/s41577-021-00639-3

46. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of nonalcoholic fatty liver disease (NAFLD). *Metabolism*. (2016) 65:1038–48. doi: 10.1016/ j.metabol.2015.12.012

47. Gruzdev SK, Podoprigora IV, Gizinger OA. Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets. *Arch Microbiol.* (2024) 206:62. doi: 10.1007/s00203-023-03752-0

48. Tham KW, Abdul GR, Cua SC, Deerochanawong C, Fojas M, Hocking S, et al. Obesity in South and Southeast Asia-A new consensus on care and management. *Obes Rev.* (2023) 24:e13520. doi: 10.1111/obr.13520

49. Ye J, Hu Y, Chen X, Yin Z, Yuan X, Huang L, et al. Association between the weight-adjusted waist index and stroke: a cross-sectional study. *BMC Public Health.* (2023) 23:1689. doi: 10.1186/s12889-023-16621-8

50. Shen Y, Wu Y, Fu M, Zhu K, Wang J. Association between weight-adjusted-waist index with hepatic steatosis and liver fibrosis: a nationally representative crosssectional study from NHANES 2017 to 2020. Front Endocrinol (Lausanne). (2023) 14:1159055. doi: 10.3389/fendo.2023.1159055

51. Chen H, Liu Y, Liu D, Liang Y, Zhu Z, Dong K, et al. Sex- and age-specific associations between abdominal fat and non-alcoholic fatty liver disease: a prospective cohort study. *J Mol Cell Biol.* (2023) 15:mjad069. doi: 10.1093/jmcb/mjad069

52. Fresneda S, Abbate M, Busquets-Cortés C, López-González A, Fuster-Parra P, Bennasar-Veny M, et al. Sex and age differences in the association of fatty liver index-defined non-alcoholic fatty liver disease with cardiometabolic risk factors: a cross-sectional study. *Biol Sex Differ*. (2022) 13:64. doi: 10.1186/s13293-022-00475-7

53. Lin G, Xinhe Z, Haoyu T, Xing J, Dan L, Ningning W, et al. Epidemiology and lifestyle survey of non-alcoholic fatty liver disease in school-age children and adolescents in Shenyang, Liaoning. *BMC Pediatr.* (2022) 22:286. doi: 10.1186/s12887-022-03351-w

54. Apostolov R, Wong D, Low E, Vaz K, Spurio J, Worland T, et al. Testosterone is lower in men with non-alcoholic fatty liver disease and alcohol-related cirrhosis and is associated with adverse clinical outcomes. *Scand J Gastroenterol.* (2023) 58:1328–34. doi: 10.1080/00365521.2023.2220857

55. Ganesh VS, Riquin K, Chatron N, Lamar KM, Aziz MC, Monin P, et al. Novel syndromic neurodevelopmental disorder caused by de novo deletion of CHASERR, a long noncoding RNA. *medRxiv*. [Preprint] (2024). doi: 10.1101/2024.01.31.24301497

56. Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the north American society of pediatric gastroenterology, hepatology and nutrition (NASPGHAN). *J Pediatr Gastroenterol Nutr.* (2017) 64:319–34. doi: 10.1097/MPG.000000000000

57. Abrams GA, Rabil AM, Williams AP, Hecht EM. Serum alanine transaminase is an inadequate nonalcoholic fatty liver screening test in adolescents: results from the national health and nutrition examination survey

2017-2018. Clin Pediatr (Phila). (2021) 60:370–5. doi: 10.1177/0009922821102 0177

58. Kang Y, Park S, Kim S, Koh H. Normal serum alanine aminotransferase and nonalcoholic fatty liver disease among Korean adolescents: a cross-sectional study using data from KNHANES 2010-2015. *BMC Pediatr.* (2018) 18:215. doi: 10.1186/s12887-018-1202-z

59. Tang A, Cloutier G, Szeverenyi NM, Sirlin CB. Ultrasound elastography and MR elastography for assessing liver fibrosis: part 2, diagnostic performance, confounders, and future directions. *AJR Am J Roentgenol.* (2015) 205:33–40. doi: 10.2214/AJR.15. 14553